Research Paper Volume 13, Issue 6 pp 8026—8039

mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction

Analysis of FGF-23, klotho, and phosphate urine excretion in the two groups of patients. As shown, we observed a significant statistical difference between the two groups of patients for the values of FGF-23, Klotho, phosphate urine excretion, indicating that patients receiving mTORi Group (B) presented reduced FGF-23 levels (A), increased Klotho levels (B) with enhanced phosphaturia (C). Interestingly, we also found a reduced left ventricular mass (LVM) in group B patients (D).

Figure 1. Analysis of FGF-23, klotho, and phosphate urine excretion in the two groups of patients. As shown, we observed a significant statistical difference between the two groups of patients for the values of FGF-23, Klotho, phosphate urine excretion, indicating that patients receiving mTORi Group (B) presented reduced FGF-23 levels (A), increased Klotho levels (B) with enhanced phosphaturia (C). Interestingly, we also found a reduced left ventricular mass (LVM) in group B patients (D).